Ocular Surface Disease Treatments in the Pipeline - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

  • By

  • Bela Parekh, MD

  • Jai G. Parekh, MD, MBA, FAAO

  • May 1, 2025

  • 7 min

Share

Clinical Scorecard: Ocular Surface Disease Treatments in the Pipeline

At a Glance

CategoryDetail
ConditionOcular Surface Disease (OSD)
Key MechanismsTear film instability, inflammation, and disruption of ocular surface homeostasis.
Target PopulationIndividuals with dry eye disease (DED), estimated at over 20 million in the U.S. and 350 million globally.
Care SettingOphthalmology and optometry clinics.

Key Highlights

  • Diverse treatment options including traditional eye drops, nasal sprays, and lacrimal occlusion.
  • Emerging therapies targeting inflammation, tear production, and specific conditions like meibomian gland dysfunction.
  • Notable candidates in development include reproxalap and AR-15512, targeting novel pathways and improving patient compliance.

Guideline-Based Recommendations

Diagnosis

  • Identify the appropriate subtype of ocular surface disease for tailored treatment.

Management

  • Utilize a multimodal approach to address symptoms and underlying pathology.

Monitoring & Follow-up

  • Regular assessment of tear film stability and ocular surface health.

Risks

  • Potential for chronic symptoms and complications if not properly managed.

Patient & Prescribing Data

Patients suffering from chronic dry eye disease and associated ocular surface conditions.

Recent advancements in therapies offer targeted mechanisms to improve outcomes.

Clinical Best Practices

  • Tailor therapies to individual patient needs and tolerance.
  • Stay updated on emerging treatments and their mechanisms of action.

Related Resources & Content

Original Source(s)

Ocular Surface Disease Treatments in the Pipeline

  • by Bela Parekh, MD, Jai G. Parekh, MD, MBA, FAAO

  • May 1, 2025

Related Content

Scleral Lens Evolution

This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.

Music May Ease Anxiety in Eye Clinics

Background music and multimedia exposure were associated with lower patient-reported anxiety in a quasi-experimental ophthalmology clinic study that used existing clinic audiovisual infrastructure at no additional cost.

Precision treatment of chalazion based on AI-driven risk stratification: a prospective study of triamcinolone acetonide combined with intense pulsed light therapy